SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

Sandra G. Adams, MD, MS
Professor, Division of Pulmonary Diseases and Critical Care Medicine
UT Health San Antonio
Staff Physician, The South Texas Veterans Health Care System
Founder, President
WipeDiseases Foundation
San Antonio, TX

Gregg Sherman, MD
Family Practice
Plantation, FL

: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Activity/Course #:
: NCME354x

: Free
Release/Start Date:
: Aug 01 2018
Expiration Date:
: Jul 31 2019
: Pulmonology
Target Audience:
: Primary Care Providers
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 0
Hardware/Software Requirements:
Program Summary
Asthma affects 18.7 million adults and 7 million children in the United States while costing $56 billion in healthcare costs and lost productivity. It is a heterogenous disorder usually characterized by chronic airway inflammation, and defined by respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation.

An understanding of the pathophysiology of asthma, type 2 inflammation, the impact of comorbid conditions, and the emergence of biologic therapies can improve outcomes for patients. In this program, the faculty will address our expanding understanding of severe asthma, how to appropriately stratify patients for biologic therapy, and the role of interdisciplinary care.

This webcast was recorded live at the Emerging Challenges Live Virtual Symposium 2018 and is being used with the permission of the presenters. 

Learning Objectives

After completing this program participants should be able to:

  1. Describe newer concepts in the pathophysiology of asthma and type 2 inflammation and the implications of biologic therapies in the era of precision medicine
  2. Determine the utility of simple biomarkers to identify patients who are candidates for targeted biologic therapies and appropriate referral
  3. Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment
  4. Discuss the paradigms of multidisciplinary care in asthma, with an emphasis on patient and provider education, to improve adherence to inhalers and emerging biologic therapies in asthma

How to obtain the CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.25 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Diego Maselli, MD, FCCP, Course Director and faculty serves as a consultant for Sunovion, Bayer, and AstraZeneca.

Dr. Sandra Adams, MD, MS, faculty and speaker, serves as researcher for AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, GlaxoSmithKline, Novartis Pharmaceuticals, and Sunovion Pharmaceuticals, Inc.

Activity Planning Committee
Gregg Sherman, MD, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Sheila Lucas, CWEP, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationship to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from AstraZeneca.